EOLS News and Press, Evolus Inc. From 11/08/22

Evolus press release ( NASDAQ: EOLS ): Q3 GAAP EPS of -$0.36 in-line. Revenue of $33.9M (+27.1% Y/Y) misses by $2.12M . Reiterates Full-Year 2022 Net Revenue Guidance at Top End of $143 to $150 Million Range; ; consensus $149.88M. Company Lowers Non-GAAP O...

Reported Sales Up 27% to $33.9 Million; Success of ‘Switch Your Tox’ Promotion Contributes to $3.5 Million Incremental Increase in Deferred Revenue Over Q2 and Understates Strength of Results ‘Switch Your Tox’ Drives Record Consumer Rewards Redemp...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November. Audio webcasts of these events...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2022 financial results and provide a business update on Tuesday, November 8, 2022, after the U.S....

Geographic expansion represents a significant step toward becoming a leading, global, multi-product performance beauty company Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, launched com...

Evolus ( NASDAQ: EOLS ) said Wednesday it concluded certain royalty payments related to the 2021 settlement of litigation claims between the company, Medytox and Allergan - which is now part of AbbVie ( ABBV ). EOLS continues to expect its adj. gross profit mar...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, this month celebrated the conclusion of certain royalty payments that resulted from the 2021 settlement of litigation claims between the company and Me...

Summary Today, we circle back on Evolus Inc. for the first time in 2022. The company is delivering impressive revenue growth and marching towards profitability in FY2024. The company continues to take market share in the aesthetic neurotoxin space. An investment analysis ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 169,158 share...

Evolus ( NASDAQ: EOLS ) on Tuesday has named Sandra Beaver as its chief financial officer, effective Sept. 5, 2022. Most recently, Beaver served as Senior Vice President of Finance at Experian ( OTCQX:EXPGF ) and previously has worked for 17 years with&#...